∙ A subject will be eligible for study participation if they meet the following criteria within 28 days prior to the first day of treatment. Historical records are permitted per investigator discretion.

• Subject must have confirmation of non-acute promyelocytic leukemia (APL) Acute Myeloid Leukemia (AML) by the World Health Organization (WHO) criteria with a monocytic or monoblastic phenotype or a Ras pathway mutation.

• The subject's AML must be relapsed after or refractory to prior treatment with hypomethylating agent (HMA) and venetoclax combination.

• Note: other prior line(s) of therapy including stem cell transplant (SCT) are allowed, but HMA/Ven must be one of the preceding treatments. Subjects who have progressed to AML after prior treatment with HMA/Ven for high grade Chronic Myelomonocytic Leukemia (CMML) or Myelodysplastic Syndrome (MDS) are also eligible.

• Age ≥ 18 years

• Projected life expectancy of at least 12 weeks

• Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2

• Adequate renal function as demonstrated by a calculated creatinine clearance ≥ 60 mL/min, calculated using the formula CKD-EPI Creatinine Equation (2021).

• Adequate liver function, as demonstrated by:

‣ Aspartate aminotransferase (AST) ≤ 3.0 x ULN\*

⁃ Alanine aminotransferase (ALT) ≤ 3.0 x ULN\*

⁃ Total bilirubin ≤ 1.5 x ULN, unless considered to be due to leukemic organ involvement or Gilbert's syndrome\* \*In subjects with Gilbert's syndrome, bilirubin needs to be ≤ 4 x ULN

• Non-sterile male subjects must use contraceptive methods with partner(s) at least prior to beginning study drug administration and continuing up to 90 days after the last dose of study drug. Male subjects must agree to refrain from sperm donation from initial study drug administration until 90 days after the last dose of study drug. No contraception is required if male subjects are surgically sterile (vasectomy with medical assessment confirming surgical success) or if the male subject has a female partner who is postmenopausal or permanently sterile (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).

• Female subjects must be either:

‣ Postmenopausal: defined as age \> 60 years with no menses for 12 or more months without an alternative medical cause; OR

⁃ Permanently surgically sterile (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy); OR

⁃ If subject is of childbearing potential, use of contraception is required while on study treatment and for 6 months after the last dose.

⁃ Subject must voluntarily sign an informed consent, approved by the Institutional Research Board (IRB), prior to the initiation of any research-related screening or study procedures.